Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTZ5NI7)

DTT Name Casein kinase II (CSNK2)
Gene Name CSNK2
DTT Type
Clinical trial target
 [1]
UniProt ID
NOUNIPROTAC
TTD ID
T84894

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
CIGB-300 DM0Q6CM Cervical cancer 2C77.0 Phase 3 [1]
CX-4945 DMWE7B9 Coronavirus infection 1D92 Phase 2 [2]
------------------------------------------------------------------------------------
1 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tetrabromocinnamic acid DMKLIXZ Discovery agent N.A. Investigative [3]
------------------------------------------------------------------------------------

References

1 Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models. Mol Clin Oncol. 2014 Nov;2(6):935-944.
2 CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia. 2013 Oct;27(10):2094-6.
3 Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007 Jan 2;8(1):129-39.